5th Nordic Pathology Meeting – Sweden 2019 5th Nordic Pathology Meeting - Sweden 2019 Försök att betygsätta följande påståenden om/inslag i kursen på en skala 1-5 med 1 som sämst och 5 som bäst.KursnamnHow good has the meeting fulfilled your expectations? 1 2 3 4 5 No opinion How much has the meeting contributed to giving you new knowledge of the subject? 1 2 3 4 5 No opinion How well did Clarion Hotel Arlanda work as a meeting venue? 1 2 3 4 5 No opinion What overall rating would you put on themeeting? 1 2 3 4 5 No opinion PD-L1 as a biomarker for IO in NSCLC (K Kerr) 1 2 3 4 5 No opinion PD-L1 on cytology (B Guldhammer Skov) 1 2 3 4 5 No opinion PD-L1 - NordiQC experiences (M Vyberg) 1 2 3 4 5 No opinion Discussions of the morning sessions (B Guldhammer Skov) 1 2 3 4 5 No opinion Other biomarker for IO, including TMB (K Kerr) 1 2 3 4 5 No opinion PD-L1 prevalence in an unselected (Danish) population (B Guldhammer Skov) 1 2 3 4 5 No opinion Clinical aspects of fusion genes in NSCLC (J Koivunen) 1 2 3 4 5 No opinion Molecular analyses of fusion genes (F Enlund) 1 2 3 4 5 No opinion Questions and answers 1 2 3 4 5 No opinion Targets beyond EGFR and ALK in NSCLC (S Ekman) 1 2 3 4 5 No opinion What to report and not to report in the molecular pathology report (J Botling) 1 2 3 4 5 No opinion Wrap-up 1 2 3 4 5 No opinion An update on the use of EGFR TKIs in NSCLC (O Terje Brustugun, ) 1 2 3 4 5 No opinion Liquid biopsies in EGFR-mutation positive patients – when to use it and which methods (J Kononen) 1 2 3 4 5 No opinion Rebiopsy in EGFR TKI treated patients – when and how? (J Kononen) 1 2 3 4 5 No opinion Breakout sessions countrywise 1 2 3 4 5 No opinion Status on IO in MPM and SCLC (Clinical) (J Benn Sørensen) 1 2 3 4 5 No opinion Delta-like protein 3 (DLL3) ADC in SCLC - (Rova-T) (S Langer) 1 2 3 4 5 No opinion MPM prognostic markers and potential therapeutic targets (O Dimitri Røe) 1 2 3 4 5 No opinion Subtyping of Malignant Mesothelioma including reproducibility of biphasic mesothelioma: Data from the MESOPATH reference center (F Galateau-Sallé) 1 2 3 4 5 No opinion Genomic Medicin Sweden (GMS) and its implication on biomarker analysis in lung cancer (R Rosenquist Brandell) 1 2 3 4 5 No opinion Discussion and Close up! (Organizing Committee) 1 2 3 4 5 No opinion Other comments on the meeting Δ
